Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual fentanyl (AD 923) vs immediate-release morphine for cancer breakthrough pain
2007-000558-30Phase 3Active
- Sponsor
- Nxera Pharma
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AD-923 in cancer pain and breakthrough pain (2 arms), sponsored by Nxera Pharma. Primary endpoint: Sum of Pain Intensity Difference (SPID) from 0 to 30 minutes. Started Oct 2007; status: active.
02
Drugs
AD-923
03
Conditions
cancer painbreakthrough pain
Beyond the preview
Go deeper on 2007-000558-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000558-30.